Extrait

The primary aim of this trial is to estimate the duration of hepatic progression-free survival (HPFS) in participants treated with bland embolization (BE), transcatheter arterial Lipiodol chemoembolization (TACE), and embolization by drug-eluting beads (DEB). The primary hypothesis is that chemoembolization will be nearly twice as durable as bland embolization; thatis, the hazard ratio for HPFS will be 1.76 or better.

Critère d'inclusion

• Adults With Unresectable Liver-dominant Neuroendocrine Tumor Metastases That Are Are Symptomatic, Progressive, or Involve 25% of the Liver Volume

Liens

• nct
• ictrp